The chimeric antigen receptor T (CAR-T) cells were genetically engineered T cells to express CARs composed of an antigen-specific scFv antibody, costimulatory domain, and intracellular T cell signaling domain for antigen-specific cytotoxicity. US FDA-approved six CAR-T products have led to remarkable regression in liquid tumors. However, there are still several hurdles encountered for the application of CAR-T cells in solid tumors, such as the immunosuppressive tumor microenvironment by PD-1 and PD-L1 axis. Development Center for Biotechnology (DCB) has developed CAR-T cells targeting Globo H, a tumor-associated carbohydrate antigen, highly expressed in several cancers. Our preliminary data suggested that Globo H CAR-T cells showed antigen-specific cytotoxicity and cytokine production in Globo H-expressing gastric and pancreatic cancer cells. Moreover, our studies indicated that the combination of Globo H CAR-T cells with anti-PD-1 or PD-L1 antibodies significantly potentiated tumor inhibition. We hypothesized that our anti-PD-L1 scFv-secreting Globo H CAR-T (Armored Globo H/ICB CAR-T) cells would overcome the immunosuppressive microenvironment for the effective treatment of Globo H-positive solid tumors.

Armored Globo H/ICB CAR-T cells
- Targeting a tumor-specific antigen, Globo H.
- Globo H/ICB CAR-T cells would overcome the immunosuppressive tumor microenvironment for the treatment of solid tumors.
- Armored Globo H/ICB CAR-T cells provide new therapeutic insight into Globo H-positive solid tumors.